Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs - Wikidata - awgldk - TriplyDB

Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs

Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs

http://www.wikidata.org/entity/Q28468294

about

Using multi-criteria decision analysis to appraise orphan drugs: a systematic review.Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis.Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis.Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion.Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?

P2860

Q48169439-9AE9A8F4-BD9A-46B9-B311-3E4A0D4E38AB Q55078013-A3A20437-D506-4B1C-9D72-5378974A1D80 Q55360994-B329397B-AD7F-44E0-B0E8-E28705891FEE Q55513066-62C8ACAA-7E40-4E70-9A48-5CC39AD94E07 Q58122261-63599D04-593E-4464-87A9-751CE28FDF5D

P2860

Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs

http://www.wikidata.org/entity/Q28468294

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Multi-criteria decision analys ...... CDA framework for orphan drugs

@ast

Multi-criteria decision analys ...... CDA framework for orphan drugs

@en

Multi-criteria decision analys ...... CDA framework for orphan drugs

@nl

type

label

Multi-criteria decision analys ...... CDA framework for orphan drugs

@ast

Multi-criteria decision analys ...... CDA framework for orphan drugs

@en

Multi-criteria decision analys ...... CDA framework for orphan drugs

@nl

prefLabel

Multi-criteria decision analys ...... CDA framework for orphan drugs

@ast

Multi-criteria decision analys ...... CDA framework for orphan drugs

@en

Multi-criteria decision analys ...... CDA framework for orphan drugs

@nl

P1433

Q28468294-BE61E043-3F78-487C-BB0E-8A6E19CFE4E8

P1476

Q28468294-DA7AF75B-E88C-4A2B-9C63-3F670E99F707

P2093

Q28468294-1C826475-42B1-40D3-9DDA-846896D8DBDC

Q28468294-2EA94A0F-E6F0-4697-BC3E-0264720F819C

Q28468294-4E1E716A-A8D6-4D7E-8AC5-68DF85B0239B

Q28468294-8C4A2457-C342-47AC-B56B-443E5108B9A1

P2860

Q28468294-08561B79-6E67-45E4-8367-D8A391F432B3

Q28468294-11C5F6A2-0AE0-4F8B-A1B1-148F5748C27B

Q28468294-156D43D7-5650-481F-937A-34CDD590863E

Q28468294-15B3CB52-7EA1-4833-9298-4C2FEF7D57C8

Q28468294-4B1B2EFE-A0AE-45EF-94CA-E48AE3DFCD35

Q28468294-52EAFE27-AACF-4164-86E1-61866F406C38

Q28468294-54EA1D54-FFC5-4E8E-B9DF-0F1FCAD3C37B

Q28468294-5783369C-8370-416E-9F00-4B75E70C48E3

Q28468294-5D76728D-86EE-4DFB-9BC7-B0F724768327

Q28468294-626C643C-B5D0-4A28-B4BD-16BC02DD0028

P2888

Q28468294-4445A8D5-DF17-4EC1-9B3E-78ED1BF7C921

P304

Q28468294-FB6D92AE-FE86-497F-B605-BAB22FC6D817

P31

Q28468294-A822E8DD-1010-4060-9CD1-068E9CE1E985

P356

Q28468294-5126E380-8BDC-44F5-A23E-C50CF80E8724

P407

Q28468294-43F6F570-2718-4A49-937B-5CF7F4A72FB5

P433

Q28468294-6295DD9C-69A6-4B41-AD8B-6EDFB1FE5F74

P478

Q28468294-00F25B9F-624D-4971-8CE1-92D87CC7D9F0

P577

Q28468294-EE50F588-5979-48CF-8814-B9A8A1001192

P6179

Q28468294-7ED34BC3-DB8A-4310-817D-59F2A3E26928

P698

Q28468294-A05F084D-B3FC-4D6B-9F5A-D5B373AA3BF1

P921

Q28468294-A492C8E8-DE61-424E-9540-495B10C34E40

P932

Q28468294-95AB4BA8-B22A-43B0-BA63-BD3C022E8FF2

P356

S13023-016-0555-3

P1433

Orphanet Journal of Rare Diseases

P1476

Multi-criteria decision analys ...... CDA framework for orphan drugs

@en

P2093

C Schey

http://www.w3.org/2001/XMLSchema#string

M J Postma

http://www.w3.org/2001/XMLSchema#string

M P Connolly

http://www.w3.org/2001/XMLSchema#string

P F M Krabbe

http://www.w3.org/2001/XMLSchema#string

P2860

Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.

Priority setting of health interventions: the need for multi-criteria decision analysis.

Multicriteria decision analysis in oncology.

Multi-criteria decision analysis for setting priorities on HIV/AIDS interventions in Thailand.

A journey of hope: lessons learned from studies on rare diseases and orphan drugs.

Information created to evade reality (ICER): things we should not look to for answers.

Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?

Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment.

Are payers treating orphan drugs differently?

Balancing efficiency, equity and feasibility of HIV treatment in South Africa - development of programmatic guidance.

P2888

s13023-016-0555-3

P304

10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13023-016-0555-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011023519

http://www.w3.org/2001/XMLSchema#string

P698

28095876

http://www.w3.org/2001/XMLSchema#string

P921

P932

5240262

http://www.w3.org/2001/XMLSchema#string